SLE and LN market expected to reach $5.9bn across 7MM by 2034
The anticipated growth is mainly driven by ten new pipeline drugs expected to be introduced to the market by 2034.
Healthcare
JPM26: Solid Biosciences banks on its AAV capsid to catalyse gene therapy success
Big pharma and investors re-engage in CGTs and race to scale
Investors bet on newer technology and indications for CGTs
Redefining clinical trials in oncology and rare diseases across the Europe
Metagenomi culls 25% of its workforce and replaces CEO in reshuffle
FDA halts uniQure’s plans for Huntington’s disease gene therapy
Sensei to ditch its lead candidate and cut workforce amidst strategic review
